Clinical Development Life Science Pharma Companies 
Pharmaceutical Technology
OCTOBER 28, 2022
Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. This helps to reduce human error and provide more reliable, replicable results and increase the speed of drug discovery and development processes.
pharmaphorum
APRIL 19, 2021
The UK’s unique offering as a life sciences research hub helped convince US biotech Novavax to develop its COVID-19 jab there, according to the head of the country’s Vaccines Taskforce. . If you look at the development, we signed 15,000 people in six weeks in a trial set up by the NHS.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
JULY 21, 2021
However, some of the key pharma companies at the global level have shifted their focus towards these diverse diseases. Through this article, we have covered the major autoimmune diseases and the key companies striving to transform the treatment landscape of the respective disease.
pharmaphorum
SEPTEMBER 3, 2020
The area is being reimagined as a life sciences and technology hub and is already home to the Francis Crick Institute biomedical research organisation. With AI the pharma industry hopes to reduce the number of drugs that fail during the clinical development process, a huge financial drain on the industry.
pharmaphorum
MARCH 9, 2021
Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants.
pharmaphorum
APRIL 19, 2021
UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery and as head of the UK vaccines taskforce. It’s been eventful 12-month period for the UK biotech guru Clive Dix, who has just seen his company C4X Discovery clinch a major inflammatory diseases deal with Sanofi.
XTalks
MAY 30, 2024
Over the years, his career has evolved from routine case processing at large pharma companies to a more strategic role in smaller settings, where he feels his impact more directly. He notes that the patient voice is critical, and with more involvement, patient advocacy groups will play an important role in clinical development.
Expert insights. Personalized for you.
311 
Let's personalize your content